Haloperidol Decanoate Monograph for Professionals - carinsurancequote1k.top
Adjustment of dosing interval may be required. Start with low dose of Most effective dose expected in range 25 - 75 mg every 4 weeks. Caution but no dose adjustment recommended.
Halve initial dose and adjust with smaller increments at longer intervals. Increased mortality in elderly with dementia. Sudden death reported rarely. Haldol decanoate not indicated for dementia-related behavioural disturbances. Caution in patients with bradycardia, cardiac disease, family history of QTc prolongation, history of heavy alcohol exposure, poor CYP2D6 metabolisers. Baseline and periodic electrolyte monitoring recommended; if abnormal, correct before treatment with haloperidol starts.
Caution in patients with hypotension or orthostatic hypotension. Caution in patients with risk factors for stroke. Withdraw treatment immediately if symptoms seen; give supportive therapy and monitor. May occur, most likely in first weeks; increasing dose may be detrimental. Preventive anticholinergic antiparkinson drugs not to be prescribed routinely but may have to be continued after stopping Haldol decanoate; possible increase in intraocular pressure with concomitant anticholinergic drugs.
Caution in epilepsy and conditions predisposing to seizures. Caution in hyperthyroidism; add therapy to achieve euthyroid state. Hormonal effects of antipsychotics include hyperprolactinaemia; caution in patients with pre-existing hyperprolactinaemia and possible prolactin-dependent tumours.
Hypoglycaemia and inappropriate antidiuretic hormone secretion reported. Patients considered for Haldol decanoate should be initially put on oral haloperidol to reduce unexpected adverse sensitivity to haloperidol. Not to be used alone where depression is predominant. Poor metabolisers of CYP2D6: Depression, insomnia, akathisia, Parkinsonism, masked facies, tremor, somnolence, sedation, constipation, dry mouth, salivary hypersecretion, muscle rigidity, sexual dysfunction, injection site reaction, weight increased.
Leukopenia, agranulocytosis, neutropenia, pancytopenia, thrombocytopenia, anaphylactic reaction, inappropriate antidiuretic hormone secretion, neuroleptic malignant syndrome, tardive dyskinesia, convulsion, tachycardia, ventricular fibrillation, Torsade de pointes, extrasystoles, acute hepatic failure, cholestasis, hepatitis, jaundice, dermatitis exfoliative, leukocytoclastic vasculitis, rhabdomyolysis, trismus, urinary retention, drug withdrawal syndrome neonatal, priapism, sudden death, electrocardiogram QT prolonged.
Preferable to avoid use in pregnancy; use only if benefit outweighs risk. Increase in haloperidol plasma concentrations: Decrease in haloperidol plasma concentrations: Enhanced CNS effect seen with methyldopa.
May antagonise effects of levodopa and other dopamine agonists. Inhibits metabolism of tricyclic antidepressants e. Rarely and mostly reversible encephalopathy, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, acute brain syndrome and coma with lithium; stop therapy immediately if symptoms occur.
Antagonism of anticoagulant phenindione. Adverse events should be reported. Reporting forms and information can be found at www. Adverse events should also be reported to Janssen-Cilag Limited on or at dsafety its. This site is published by Janssen-Cilag Limited, which is solely responsible for the content. It is intended for a UK healthcare professional audience.
Refer to SmPC for other side effects. Refer to SmPC for full details of interactions. Prescribing information last revised: June Adverse events should be reported.
June This site is published by Janssen-Cilag Limited, which is solely responsible for the content.